LupusTrials.org The primary objectives of the study are to evaluate the efficacy of BIIB059 compared with placebo in reducing skin disease activity measured by the Cutaneous Lupus Activity of Physician’s Global Assessment-Revised (CLA-IGA-R) score [Parts A and B (US)] and the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) score [Part B (ROW)] in …
Archives: Trials
A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus
CATEGORIES: General SLE First posted November 17, 2021, Updated September 9, 2022; Recruiting The main purpose of this study is to assess the efficacy and safety of LY3361237 in participants with at least moderately active systemic lupus erythematosus (SLE). Study will last up to 34 weeks and may include up to 15 visits. To Learn …
Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis
September 16, 2022 CATEGORIES: Lupus Nephritis First posted September 15, 2022, Updated September 15, 2022 This trial aims to learn about the safety and tolerability of daxdilimab (trial drug), and to learn about the effect it has on lupus nephritis when combined with standard treatment (that is, mycophenolate mofetil [MMF] or mycophenolic acid [MPA] and …
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Stage Trial to Evaluate Efficacy and Safety of Telitacicept Compared to Placebo in Patients with Moderately to Severely Active Systemic Lupus Erythematosus
CATEGORIES: General SLE First posted April 1, 2022, Updated July 11, 2022; Recruiting The purpose of this Phase 3 study is to evaluate the efficacy and safety of telitacicept in the treatment of moderately to severely active SLE. To Learn More Contact Call RemeGen at 301-284-1015 or by email to RC18_SLEstudy@remegenbio.com ClinicalTrials.gov identifier (NCT number): NCT05306574 …
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis (IRIS)
CATEGORIES: Lupus Nephritis First posted November 30, 2021, Updated August 10, 2022; Recruiting This Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of anifrolumab versus placebo as added to SOC (consisting of MMF and glucocorticoids) in adults with active proliferative Class III or Class IV LN (both with or …
ELEVATE – (Empower Lupus Erythematosus Patients Via Allowing RemoTe Evaluation) (ELEVATE)
First posted April 27, 2022, Updated May 5, 2022; Recruiting CATEGORIES: General SLE The purpose of this large observational trial is to explore the potential for use of DxTerity’s AIP IFN-1 test as personalized guided care and monitoring module in patients with Systemic lupus erythematosus(SLE) using consented patient health information To Learn More Contact Deepti Sood …
PRV-3279-2a Trial in Systemic Lupus (PREVAIL-2)
First posted October, 2021, Updated January, 2022; Recruiting CATEGORIES: Lupus The purpose of this Phase 2a PREVAIL-2 trial is to assess the safety and potential efficacy of PRV-3279 in flare prevention in systemic lupus erythematosus (SLE) patients with active disease after amelioration induced by corticosteroid treatment. To Learn More Contact Clinical Operations at 857-675-1664 or …
A novel Phase 2 double-blind, randomized, controlled clinical trial to evaluate the efficacy of centrally acting, non-toxic ACE inhibition in cognitive impairment associated with SLE
First posted July, 2020, Updated November, 2021; Recruiting CATEGORIES: CNS Lupus This research study is being done to test the effects of centrally-acting ACE inhibitor, named lisinopril, on resting metabolism in the brain and on cognitive function. The investigators will see if Lisinopril will decrease resting metabolism in the brain and improve cognitive function (memory …
Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
First posted September, 2020, Updated September, 2021; Recruiting CATEGORIES: Lupus Nephritis The objectives of this Phase 2, Double-Blind, Randomized, Placebo-Controlled Study is to evaluate the efficacy and safety of ravulizumab in adult participants With proliferative lupus nephritis (LN) or immunoglobulin A nephropathy (IgAN) To Learn More Contact Contact: Alexion Pharmaceuticals, Inc.at 855-752-2356 or clinicaltrials@alexion.com ClinicalTrials.gov identifier: …
Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus
First filed December 23, 2020, Updated July 2022; Recruiting CATEGORIES: General SLE The purpose of this Phase 2 study is to evaluate the efficacy and safety of efavaleukin alfa in subjects with active SLE. This study is being offered at 20 LuCIN sites – institutions that are members of the Lupus Clinical Investigators Network managed …